Myoglobin induces vascular cell adhesion molecule-1 expression through c-Src kinase-activator protein-1/nuclear factor-kappaB pathways

Nephron Exp Nephrol. 2010;114(2):e48-60. doi: 10.1159/000254391. Epub 2009 Nov 3.

Abstract

Background/aims: It is not clear whether a sublethal dose of myoglobin induces some pathophysiological changes in tubular cells, potentially affecting tubular injury or tubular regeneration. We investigated the effect of a low dose of myoglobin on vascular cell adhesion molecule-1 (VCAM-1) expression and elucidated the underlying signaling pathways. We further examined the effect of losartan and simvastatin on myoglobin-induced VCAM-1 expression and the signaling pathways.

Methods: Activation of nuclear factor (NF)-kappaB and activator protein (AP)-1 was assessed by electrophoretic mobility shift assay. Phosphorylation of protein kinases was examined by Western blot analysis. VCAM-1 mRNA and protein were measured by Northern blot analysis and cell ELISA.

Results: A sublethal dose of myoglobin (100 microg/ml) induced VCAM-1 expression via activation of AP-1 and NF-kappaB, which was mediated through activation of c-Src kinase, followed by mitogen-activated protein kinases (p38, ERK 1/2, JNK-1) and the I kappaB kinase - I kappaB-alpha. Inhibitors of protein kinase C and tyrosine kinase, antioxidants and intracellular calcium chelator suppressed myoglobin-induced activation of c-Src kinase. Losartan and simvastatin suppressed myoglobin-induced VCAM-1 expression via inhibition of c-Src kinase.

Conclusion: VCAM-1 expression via c-Src kinase-AP-1/NF-kappaB pathways might be one of the possible mechanisms linking myoglobin to tubular injury. Losartan and simvastatin might be beneficial in attenuating myoglobin-induced tubular injury.

MeSH terms

  • Antioxidants / pharmacology
  • CSK Tyrosine-Protein Kinase
  • Calcium / physiology
  • Cells, Cultured
  • Enzyme Activation
  • Extracellular Signal-Regulated MAP Kinases / metabolism
  • Humans
  • Losartan / pharmacology
  • MAP Kinase Signaling System / drug effects
  • Myoglobin / pharmacology
  • Myoglobin / physiology*
  • NF-kappa B / physiology*
  • Protein Kinase C / metabolism
  • Protein-Tyrosine Kinases / antagonists & inhibitors
  • Protein-Tyrosine Kinases / metabolism*
  • Simvastatin / pharmacology
  • Transcription Factor AP-1 / physiology*
  • Vascular Cell Adhesion Molecule-1 / biosynthesis*
  • src-Family Kinases

Substances

  • Antioxidants
  • Myoglobin
  • NF-kappa B
  • Transcription Factor AP-1
  • Vascular Cell Adhesion Molecule-1
  • Simvastatin
  • Protein-Tyrosine Kinases
  • CSK Tyrosine-Protein Kinase
  • src-Family Kinases
  • CSK protein, human
  • Protein Kinase C
  • Extracellular Signal-Regulated MAP Kinases
  • Losartan
  • Calcium